Vertex Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Issued FY24 Product Revenue Guidance Above Estimates. Also, Morgan Stanley Maintained an Equal-Weight Rating on the Stock and...

福泰製藥股票交易上漲，公司公佈了強於預期的第三季度財務結果，併發布了FY24產品營業收入指導高於估計。此外，摩根士丹利維持對該股票的等權重評級，...

Benzinga · 11/05 23:23

Vertex Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Issued FY24 Product Revenue Guidance Above Estimates. Also, Morgan Stanley Maintained an Equal-Weight Rating on the Stock and Raised Its Price Target From $473 to $476.

福泰製藥股價上漲，公司公佈了好於預期的Q3財務業績，併發布了FY24產品營業收入指導高於預期。此外，摩根士丹利仍然維持對該股票的等權重評級，並將其價格目標從473美元上調至476美元。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。